ArticleHuman vaccines & immunotherapeutics2016
Bio-inspired virus-like nanovesicle for effective vaccination.
Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Activation of cancer immunotherapy by nanomedicine.Frontiers in pharmacology · 2022Review
- Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities.Frontiers in medicine · 2021Review
- Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus.Vaccine · 2020Review
- Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells.Journal of biotechnology · 2019Article
- Latest advances in extracellular vesicles: from bench to bedside.Science and technology of advanced materials · 2019Review
- Extracellular vesicles as an efficient nanoplatform for the delivery of therapeutics.Human vaccines & immunotherapeutics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing effective vaccines is of vital importance for protecting public health by preventing potential pandemics or by controlling ongoing ones. However, there is a threshold of rapidly design and develop effective vaccines to prevent virus infection. Inspired by the natural budding processes associated with cell membrane scission when enveloped viruses invade host cells and replicate themselves, a similar strategy was applied to achieve virus-mimetic nanovesicles (VMVs). This strategy loaded genetically engineered viral antigens onto mammalian cell membranes to produce antigen-loaded vesicles, and then used surfactants to optimize their size and stability. The VMVs resemble natural viruses in size, shape and specific immune function and have protein antigens in the correct conformation on their exterior to elicit robust immunogenicity. This was confirmed in animal models against influenza A (H1N1) virus, demonstrating that VMVs could be a versatile platform for vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.